Quarterly intravenous injection of ibandronate to treat osteoporosis in postmenopausal women.

There was no significant difference between ibandronate groups, but the increases were statistically significantly different from placebo for the 0.5 mg (p < 0.006), 1 mg (p < 0.004), and 2 mg (p < 0.001) groups and there was a clear trend favoring the 2 mg dose at 12 months ( Figure 2 ).

also in 19,460 other papers